

# Biobased investment climate in the Netherlands and Europe

#### Summary results quick scan

Roald Suurs, researcher / advisor, TNO Elsbeth Roelofs, senior business consultant, TNO

**April 2014** 

Publication available at www.tno.nl

You might also be interested in:

http://www.industrialbiotech-europe.eu/

https://www.tno.nl/downloads/Biobased%20economy.pdf



### Introduction

The Dutch government wants to provide a fertile investment climate for innovative companies with biobased ambitions. Therefore, the ministry of Economic Affairs has asked TNO to conduct a 'quick scan' assessment.



Source picture: www.5barg8.com

- > The following questions are central in this quickscan:
  - 1. Which **criteria determine the outcome** of planning biobased investment decisions?
  - 2. What is the **relative country performance** within and outside Europe?
  - 3. What are the **specific barriers** for investing in the Netherlands and Europe?



# Approach & Scope (1/2)

Top-down
Literature
&
Interviews
(N=5)

Identify investing factors

Country performance

- Identify investing factors
- Country performance

Identify investing factors

Country performance

Europe



USA, Brazil



Thailand



Bottom-up Interviews (N=12) Experience of biobased entrepreneurs

Concrete drivers and barriers as experienced

The Netherlands





# Approach & Scope (2/2)

#### Differentiaton across the 'innovation funnel'

Semi-commercial scale demo plant meant to validate a business case.
(10-50M Euro)

R&D Demonstration Commercial production


 Expansion of R&D capacity / pilots on lab-scale. (1-10M Euro) Expansion of production capacity based on proven technology and proven business case. (>50M Euro)

#### Focus on biobased chemical companies

- Excluding companies that exclusively produce bioenergy and biofuels.
- Excluding companies that exclusively produce feed and food.




## Criteria determining biobased investment decisions (1/2)



For each type of investment the figure shows the **average weight of each criterion considered** for deciding on a go/no-go and/or chosing a location. Weights are calculated on the basis of a collection of 'top 5' rankings. A weight of 5 stands for an average rank score of 1; a weight of 1 stands for an average rank score of 5; a weight of 0 means absence from any individual top 5).



## Criteria determining biobased investment decisions (2/2)



This graph shows the **relative weight of the criteria considered** when making investment decisions with respect to go/no-go or location. Like for the previous figure, weights are calculated on the basis of a collection of 'top 5' rankings.







## R&D capacity / pilot plants

- Generally speaking, investments are drawn to regions where professionals with the relevant knowledge are situated.
- The knowledge infrastructure, in terms of organisations, facilities, education is key in attracting and supporting these professionals.
- Public financing (i.e. subsidies) are a lifeline for biobased pre-competitive R&D.
- Biobased clusters are important for their network effects, pilot facilities and especially for their 'marketing power'.




# Demonstration plants / semi-commercial

- Access to sufficient quantities of biomass feedstock at predictable and affordable costs is a requirement.
- Investors seek to minimise high costs and risks associated with this stage.
   Policy support is crucial in most cases.
- Investors look for a fit with the existing site infrastructure (e.g. steam supply, heat outlet, logistics, safety services).
- Energy costs are a cost determining factor in the (bio) chemical industry.











# Commercial production / Upscaling

- Policy is of minor importance as the business case is leading.
- Access to biobased markets is becoming more important. Whether this affects a location decision depends on type of product and company.
- Labour market conditions (e.g. costs and quality of operators) are key.
- Feedstock, infrastructure and energy costs remain important criteria.



## **Country comparison**

#### **EU** weaknesses

- · Feedstock costs and security of supply
- Energy costs
- Tax pressure / lacking financial incentives
- · Lack of 'valley of death' capital

#### **EU** strengths

- R&D support (subsidies / policies)
- Knowledge infrastructure
- Logistics infrastructure (port / inland)
- Emerging biobased niche markets

#### Within Europe differences are relatively small

	<u>Europe</u>				N-America	S-America	<u>Asia</u>	
	NL	BE	DE	FR	VS	Brazilië	Thailand	China
Feedstock: costs and availability	-	-	-	-	++	++	++	?
Utilities: energy costs	-	-	-	-	++	+	+	++
Infrastructure: logistics	++	++	+	+	+	+	+	+
Knowledge infrastructure	++	++	++	++	++	?	?	?
Regulation: R&D support	++	++	++	++	++	?	?	Ş
Regulation: incentives / taxes	-	-	-	-	+	?	++	++
Entrepreneurial culture	+	?	-	+	++	?	?	,
Market access / demand	*	*	*	*	*	*	*	*

Country comparison of key decision making criteria for allocating of biobased investments.


- ? Unknown / Ambiguous
- \* Company or product specific




#### Zoom in: feedstock costs

FEEDSTOCK COST

DOLLARS PER BARREL OF OIL EQUIVALENT



SOURCES: TIMBER MART-SOUTH, EIA, USDA, INTERNATIONAL MONETARY FUND, PNNL HYDROGEN RESOURCE CENTER, KIOR ANALYSIS




- Wood prices (chips, pellets) in the EU are about three times higher than in the USA.
- Cost levels in the EU are modest where wood residues can be collected and transported over short distance. Still the prices are volatile.
- Global prices of sugar are currently highly volatile. Potential for upscaling sugar production seems to lie especially in Brazil and SE Asia.



## Zoom in: policy incentives


- A key strength of EU is the policy support for R&D.
- The EU has trouble supporting companies in bridging the 'valley of death'.
  - Tax levels are relatively high
  - Lack of demand-side policies / public procurement initiatives
- Licensing is important for chosing specific locations within a country, but only all other business requirements have been met.





# Zoom in: knowledge infrastructure

- The USA and the EU are globally considered leading in biobased R&D.
- Growing competition is to be expected from China and Brazil.
- Note that important differences do exist between EU countries.
- The figure provides a crude estimation of strengths in terms of R&D spending in general (not specific for biobased).



Global R&D spending 2011. Size of circle reflects the relative amount of annual R&D spending by the country noted. Source: 2012 Global R&D Funding Forecast.



## **Zoom in: Energy costs**

- Energy prices are lowest in China and the USA.
- > For the EU, energy prices are relatively high. Within the EU price differences are less significant.
- Cheap energy on the basis of coal (China) and shale gas (USA) comes with high ecological costs. Some biobased businesses consider this a liability.


### How much does electricity cost?



Data: average prices from 2011 converted at mean exchange rate for that year Sources: IEA, EIA, national electricity boards, OANDA shrinkthatfootprint.com

#### Comparing the price of gas in the EU 15 and USA, 2012

Prices inc taxes, pence per kWh



No data on Belgium and Luxembourg

Source: Ofgem



### Important barriers experienced for the Netherlands (1/2)

#### High feedstock costs / availability

- Subsidies for bioenergy seem to create artificially high prices for biomass
- Lack of incentives for farmers to innovate
  - e.g. sugar quota
- Regional biomass supply is insecure
- Waste legislation is not adapted to circular economy concept

#### Lack of 'valley of death' capital

- Lack of risk capital
- Lack of government procurement programmes
- Conditions of government financing are often unfit for commercial parties:
  - Obligation to form consortia
  - Obligation to disclose knowledge



### Important barriers experienced for the Netherlands (2/2)

#### Limited market value biobased products

- Lack of market incentives for biobased products
- Limited consumer awareness of (advantages of) biobased products
- No level playing field for fossil and biobased applications

#### **Burden of regulation**

- > REACH requirements press on biobased businesses (especially SMEs)
- Permit procedures (province, municipalities) take too much time

#### Fragmentation and lack of critical mass

- Biobased initiatives are spread too thin
- Lack of cooperation between regions
- Lack of international cooperation across Europe



## Finally: some issues for discussion

- In the face of international competition, what role is there for a European biobased chemical industry? Which businesses in the Netherlands are part of that?
- Which possibilities are there for strengthening the position of European feedstock producers? Which role is there for Dutch forestry, agriculture and waste processors?
- How can the Dutch and EU governments mitigate the risks of biobased investments, most importantly for the support of demonstrations plants?
- Which possibilities are there for developing biobased markets within Europe and the Netherlands? How to stimulate consumer uptake of biobased products?